UK Scientists To Conduct TCM Research
This article was originally published in PharmAsia News
Executive Summary
Stephen Minger, Director of the Stem Cell Biology Laboratory at King's College London and senior lecturer at Wolfson Centre for Age Related Diseases, has lately been making frequent trips to China to conduct TCM research. At a recent Sino-UK biomedical innovation seminar in Shanghai, Minger expresses confidence in the effectiveness of TCM. He is collaborating with relevant Chinese institutions to screen local herbal extracts t have stimulating effect on brain cells to identify the active components. However, he notes that the functional, biological and chemical reactivity mechanisms of most Chinese medicines remain unclear, critical factors that hinder TCM's international recognition. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.